Pimicotinib in Tenosynovial Giant Cell Tumor (TGCT)

In this episode of SARC Talk Journal Club, our panel discusses the MANEUVER Phase III trial published in The Lancet, evaluating pimicotinib versus placebo in patients with tenosynovial giant cell tumor (TGCT). We review the study design, efficacy, safety profile, and patient-reported outcomes while exploring what these findings could mean for the treatment of unresectable, symptomatic TGCT.Join us as we examine the evidence behind this promising CSF-1R inhibitor and discuss its potential impact on clinical practice and future research in sarcoma.